Seminari di Ematologia Oncologica - Società Italiana di Ematologia

71. Tucci A, Cerqui E, Ungari M, et al. Continuous oral
cyclophosphamide and prednisolone as valuable
treatment option for peripheral T cell lymphoma.
[Abstract]. Br J Haematol. 2011; 152: 113-6.
72. Gallamini A, Zaja F, Patti C, et al. Alemtuzumab
(Campath-1H) and CHOP chemotherapy as first-line
treatment of peripheral T-cell lymphoma: results of a
GITIL (Gruppo Italiano Terapie Innovative nei Linfomi)
prospective multicenter trial. Blood. 2007; 110:
2316-32.
73. Kim JG, Sohn SK, Chae YS, et al. Alemtuzumab plus
CHOP as front-line chemotherapy for patients with
peripheral T-cell lymphomas: a phase II study. Cancer
Chemother Pharmacol. 2007; 60: 129-34.
74. Foss FM. Enhancing existing approaches to Periheral
T Cell Lymphomas. Semin Hematol. 2010; 47: 8-10.
75. Reimer P, Rüdiger T, Geissinger E, et al. Autologous
stem-cell transplantation as first-line therapy in
peripheral T-cell lymphomas: results of a prospective
multicenter study. J Clin Oncol. 2009; 2: 106-13.
76. Rodríguez J, Conde E, Gutiérrez A, et al. Frontline
autologous stem cell transplantation in high-risk
peripheral T-cell lymphoma: a prospective study
from The Gel-Tamo Study Group. Eur J Haematol.
2007; 79: 32-8.
77. Mounier N, Gisselbrecht C, Brière J, et al. All aggressive
lymphoma subtypes do not share similar outcome after
front-line autotransplantation: a matched-control analysis
by the Groupe d'Etude des Lymphomes de l'Adulte
(GELA). Ann Oncol. 2004; 15: 1790-7.
78. Corradini P, Dodero A, Zallio F, et al. Graft-versuslymphoma
effect in relapsed peripheral T-cell non-
Hodgkin’s lymphomas after reduced-intensity
conditioning followed by allogeneic transplantation of
hematopoietic cells. J Clin Oncol. 2004; 22: 2172-6.
79. Dodero A, Spina F, Narni F, et al. Allogeneic stem cell
transplantation (Allo-SCT) follonig a reduced intensity
conditioning (RIC) regimen in relapsed Peripheral T cell
Lymphomas (PTCL): results at 4 years of median follow
up. [Abstract]. Blood. 2009; 114 (22): 875.
80. Zain MJ, O’Connor O. Targeted treatment and new
agents in peripheral T cell lymphoma. Int J Hematol.
2010; 92: 33-44.
81. Sirotnak FM, DeGraw JI, Moccio DM, et al. New folte
analogs of the 10-deaza-aminopterin series: basis for
structural design and biochemical and pharmacologic
properties. Cancer Chemother Pharmacol. 1984; 12:
18-25.
82. O’Connor O, Pro B, Pinter-Brown LL. Results of the
pivotal, multicenter, phase II study of pralatrexate in
patients with relapsed or refractory peripheral T cell
lymphoma (PTCL). [Abstract]. J Clin Oncol. 2009; 27:
15s (8561).
83. Horwitz S, Vose J, O’Connor O. A phase 1/2 A open
label study of Pralatrexate and Gemcitabine in patients
with relapsed or refractory lymphoproliferative
malignancies. ASH 2010, [abstract] 1674.
Linfomi non Hodgkin T/NK
84. Coiffier B, Pro B, Prince M, et al. Final results from a
pivotal, multicenter, international, open-label, phase 2
study of Romidepsin in progressive or relapsed
Peripheral T Cell Lymphoma (PTCL) following prior
systemic therapy. [Abstract]. Blood. 2010; 116 (21): 114.
85. Bartlett NY, Younes A, Carabasi MH. A phase I
multidose study of SGN-30 immunotherapy in patients
with refractory or recurrent CD30+ hematologic
malignancies. Blood. 2008; 111: 1848-54.
86. Younes A, Bartlet NL, Leonard JP, et al. Brentuximab
vedotin (SGN-35) for relapsed CD30-positive
lymphomas. N Engl J Med. 2010; 363: 1812-21.
87. Shustov RA, advani R, Brice P, et al. Complete
remission with Brentuximb Vedotin (SNG-35) in patients
with relapsed or refractory Sistemic Anaplastic Large
cell Lymphoma. [Abstract]. Blood. 116 (21): 961.
88. Gambacorti-Passerini CB, Dilda I, Giudici G, et al.
Clinical activity of Crizotinib in advanced,
chemoresistance ALK+ lymphoma patient. [Abstract].
Blood. 2010; 116: 2877.
89. Butrynski JE, D'Adamo DR, Hornick JL, et al. Crizotinib
in ALK-rearranged inflammatory myofibroblastic tumor.
N Engl J Med. 2010; 363: 1727-33.
90. Huang ML, Jiang Y, Liu WP, et al. Early or up-front
radiotherapy improved survival of localized extranodal
T/NK-cell lymphoma, nasal type in the upper
aerodigestive tract. Intern J Radiat Oncol Biol Phys.
2008; 70: 166-74.
91. Wang B, Lu JJ, et al. Combined chemotherapy and
external beam radiation for stage IE and IIE natural killer
T-cell lymphoma of nasal cavity. Leuk Lymph. 2007;
48: 396-402.
92. Suzuki R, Takeuchi K, Oshima K, et al. Extranodal NK/T
cell lymphoma: diagnosis and treatment cues. Heamtol
Oncol. 2008: 26: 66-72.
93. Yamaguchi M, Kita K, Miwa H, et al. Frequent
expression of P-glycoprotein/MRD1 by nasal T-cell
lymphoma cells. Cancer. 1995; 76: 2351-6.
94. Jaccard A, Petit B, Girault S, et al. L-Asparaginase
based treatment of 15 western patients with extranodal
NK/T cell lymphoma and leukemia and a review of the
literature. Ann Oncol. 2009; 20: 110-6.
95. Yong W, Zheng W, Zhu J, et al. L-Asparaginase in the
treatment of refractory and relapsed extranodal NK/T
cell lymphoma, nasal type. Ann Hematol. 2009; 88:
647-52.
96. Jaccard A, Gachard N, Marin B, et al. Efficacy of Lasparaginase
with methotrexate and dexamethasone
(AspaMetDex regimen) in patients with refractory or
relapsing extranodal NK/T-cell lymphoma, a phase 2
study. Blood. 2011; 117: 1834-9.
97. Yamaguchi M, Suzuki R, Kwong YL, et al. Phase I trial
of dexamethasone, methotrexate, ifosfamide, Lasparaginase
and etoposide (SMILE) chemotherapy for
advanced stage, relapsed or refractory extranodal
natural killer (NK)/T cell lymphoma and leucemia.
Cancer Sci. 2008; 99: 1016-20.
79